Cargando…

Myocardial infarction associated with erenumab: A case report

BACKGROUND: Monoclonal antibodies acting on the calcitonin gene‐related peptide or its receptor (CGRP‐mabs) are novel drugs for resistant migraine prophylaxis. As CGRP‐mabs cause inhibition of vasodilatation, their use is reserved to patients with no recent history of cardiovascular diseases. We rep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perino, Justine, Corand, Virginie, Laurent, Elise, Théophile, Hélène, Miremont‐Salamé, Ghada, Pariente, Antoine, Colas, Jean‐Laurent, Couffinhal, Thierry, Salvo, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541222/ https://www.ncbi.nlm.nih.gov/pubmed/35620946 http://dx.doi.org/10.1002/phar.2706

Ejemplares similares

Second‐degree burn induced by high‐concentration topical capsaicin with mobility sequelae: A case report
por: Trin, Kilian, et al.
Publicado: (2022)

Hospitalisations après consommation de substances psychoactives pendant la pandémie de COVID-19
por: Dumoulin, Claire, et al.
Publicado: (2023)

Spontaneous Reports of Serious Adverse Drug Reactions Resulting From Drug–Drug Interactions: An Analysis From the French Pharmacovigilance Database
por: Létinier, Louis, et al.
Publicado: (2021)

Validation of Artificial Intelligence to Support the Automatic Coding of Patient Adverse Drug Reaction Reports, Using Nationwide Pharmacovigilance Data
por: Martin, Guillaume L., et al.
Publicado: (2022)

Artificial Intelligence for Unstructured Healthcare Data: Application to Coding of Patient Reporting of Adverse Drug Reactions
por: Létinier, Louis, et al.
Publicado: (2021)

The role of erenumab in the treatment of migraine
por: Andreou, Anna P., et al.
Publicado: (2020)

Gender Differences in 3-Month Outcomes of Erenumab Treatment—Study on Efficacy and Safety of Treatment With Erenumab in Men
por: Ornello, Raffaele, et al.
Publicado: (2021)

Vascular safety of erenumab for migraine prevention
por: Kudrow, David, et al.
Publicado: (2020)

Clinic and genetic predictors in response to erenumab
por: Zecca, Chiara, et al.
Publicado: (2022)

Lichenoid drug eruption induced by erenumab
por: Musicante, Meryl, et al.
Publicado: (2022)

Assessment and characteristics of Erenumab therapy on migraine management
por: Saeed, Haitham, et al.
Publicado: (2022)

A longitudinal clinical and MRI evaluation of the treatment with erenumab
por: Coccia, Alberto, et al.
Publicado: (2020)

Predictors of response to erenumab after 12 months of treatment
por: Baraldi, Carlo, et al.
Publicado: (2021)

Timing and durability of response to erenumab in patients with chronic migraine
por: Tepper, Stewart J., et al.
Publicado: (2021)

Efficacy and Tolerability of Erenumab for Prevention of Episodic Migraine in India
por: Chowdhury, Debashish, et al.
Publicado: (2022)

Erenumab in the Treatment of Comorbid Trigeminal Neuralgia in Patients With Migraine
por: Katsuki, Masahito, et al.
Publicado: (2023)

Efficacy and safety of erenumab in women with a history of menstrual migraine
por: Pavlovic, Jelena M., et al.
Publicado: (2020)

Early onset of efficacy with erenumab in patients with episodic and chronic migraine
por: Schwedt, Todd, et al.
Publicado: (2018)

Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
por: Manickam, Agaath Hedina, et al.
Publicado: (2021)

Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes
por: De Matteis, Eleonora, et al.
Publicado: (2022)

Serum CGRP in migraine patients using erenumab as preventive treatment
por: de Vries Lentsch, Simone, et al.
Publicado: (2022)

Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer
por: Allouchery, Marion, et al.
Publicado: (2020)

Migraine Treatment Using Erenumab: Can Lead to a Cognitive and Psychological Qualitative Improvement?
por: Torrisi, Michele, et al.
Publicado: (2023)

A prospective real-world analysis of erenumab in refractory chronic migraine
por: Lambru, Giorgio, et al.
Publicado: (2020)

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
por: Raffaelli, Bianca, et al.
Publicado: (2019)

Additive Interaction Between Onabotulinumtoxin-A and Erenumab in Patients With Refractory Migraine
por: Silvestro, Marcello, et al.
Publicado: (2021)

Association between response to triptans and response to erenumab: real-life data
por: Frattale, Ilaria, et al.
Publicado: (2021)

MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
por: Belvís, Robert, et al.
Publicado: (2021)

Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
por: Alsaadi, Taoufik, et al.
Publicado: (2022)

Improved Osteoarthritis during Erenumab Treatment for Migraine: A Case Report
por: Jantzen, Frederik Thal, et al.
Publicado: (2023)

A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study
por: Yu, Shengyuan, et al.
Publicado: (2022)

One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study
por: Goadsby, Peter J., et al.
Publicado: (2020)

Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial
por: Tepper, Stewart J., et al.
Publicado: (2019)

Migraine induction with calcitonin gene-related peptide in patients from erenumab trials
por: Christensen, Casper Emil, et al.
Publicado: (2018)

Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
por: Ornello, Raffaele, et al.
Publicado: (2020)

Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials
por: Di Tanna, Gian Luca, et al.
Publicado: (2019)

Erenumab for headaches in idiopathic intracranial hypertension: A prospective open‐label evaluation
por: Yiangou, Andreas, et al.
Publicado: (2020)

Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series
por: Ornello, Raffaele, et al.
Publicado: (2021)

Impact of COVID-19 on chronic migraine treated with erenumab: a case report
por: Grassini, Alberto, et al.
Publicado: (2021)

A real‐world, observational study of erenumab for migraine prevention in Canadian patients
por: Becker, Werner J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4oc0s0m8cc97o54sha9ip4q0g9